From: Vaccination process evaluation at COVID-19 vaccination centers in Lebanon: a national study
Quartile | Range | Private, N (%) | Governmental, N (%) | P-value |
---|---|---|---|---|
Transportation | > 75 | 24 (100.0) | 9 (100.0) | – |
Handling and storage | 50–75 | 3 (12.5) | 0 | 0.545 |
> 75 | 21 (87.5) | 9 (100.0) | ||
Vaccine preparation | < 50 | 1 (4.2) | 0 | 1.000 |
50–75 | 4 (16.7) | 2 (22.2) | ||
> 75 | 19 (79.2) | 7 (77.8) | ||
Pfizer preparation | 50–75 | 2 (15.4) | 2 (28.6) | 0.587 |
> 75 | 11 (84.6) | 5 (71.4) | ||
AstraZeneca preparation | > 75 | 11 (100.0) | 2 (100.0) | – |
Pre-vaccination | < 50 | 3 (12.5) | 1 (11.1) | 0.314 |
50–75 | 0 (0.0) | 1 (11.1) | ||
> 75 | 21 (87.5) | 7 (77.8) | ||
Administration | > 75 | 24 (100.0) | 9 (100.0) | – |
Post-vaccination | 50–75 | 4 (16.7) | 2 (22.2) | 1.000 |
> 75 | 20 (83.3) | 7 (77.8) | ||
Total | > 75 | 24 (100.0) | 9 (100.0) | – |